Last reviewed · How we verify
NCT03750890
Visual Study of Molecular Genotype in Glioma Evolution
trial in Glioma of Brain in 1,000 participants. Status unknown.
31 December 2021
Quick facts
| Lead sponsor | Tongji Hospital |
|---|---|
| Status | Status unknown |
| Study type | OBSERVATIONAL |
| Enrollment | 1,000 |
| Start date | 1 January 2019 |
| Primary completion | 31 December 2021 |
| Estimated completion | 31 December 2022 |
| Sites | 1 location across China |
Conditions studied
- Glioma of Brain — all drugs for Glioma of Brain →
Sponsor
Tongji Hospital
Who can join
Eligibility, any sex, with Glioma of Brain. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The key molecular changes in the progression of glioma are closely related to tumor heterogeneity, pathological grade, precision treatment and prognosis of glioma. At present, a visually quantitative assessment criteria about the key molecular typing of glioma is still absent. Based on the previous research, this project intends to establish a multi-dimensional database of glioma from clinical, radiomics and microomics levels. The investigators aim to filter out the specific molecular markers in the progression of glioma and explore the intrinsic connection of radiomics features and microomics molecular markers by using bioinformatics integration analysis and artificial intelligence multiple kernel learning. Thus, the investigators could determine the specific molecular mechanism in the progression of glioma, and establish a visually quantitative assessment system of pre-operative precisive grading, molecular typing discrimination and prognosis prediction. The completion of this project is of great significance for improving molecular diagnostic level of glioma, guiding individualized diagnosis and treatment decisions, and improving the survival rate of patients.
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
Human TERT promoter mutations as a prognostic biomarker in glioma.
Powter B, Jeffreys SA, Sareen H, Cooper A, et al · · 2021 · cited 50× · PMID 33547950 · DOI 10.1007/s00432-021-03536-3
Verify or expand the search:
- PubMed search for NCT03750890
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Glioma of Brain
Currently open trials in the same condition.
- NCT03935685 — Pilot Study of Mirtazapine for the Dual Tx of Depression and CINV in High-Grade Glioma Pts on TMZ · Phase 2 · active not recruiting
- NCT03739372 — Clinical Benefit of Using Molecular Profiling to Determine an Individualized Treatment Plan for Patients With High Grade · NA · active not recruiting
- NCT03534050 — Neuropsychological and Oncological Outcomes in Grade 2 or 3 Glioma Patients Undergoing Postoperative Modern Radiotherapy · Phase 2, PHASE3 · recruiting
- NCT03849430 — Longitudinal Analysis of the Health-related Quality of Life in Glioma Patients · recruiting
Other Tongji Hospital trials
Trials by the same sponsor.
- NCT07537946 — Local Consolidation After Sintilimab Plus Lenvatinib for Metastatic Liver Cancer · Phase 3 · not yet recruiting
- NCT07537972 — Denosumab Strategy for Liver Cancer With Bone Metastases · Phase 2 · not yet recruiting
- NCT07537959 — Surgery Plus Systemic Therapy for Liver Cancer With Extrahepatic Metastases · NA · not yet recruiting
- NCT07527260 — Effects of Adenoidectomy on Symptoms and IgE Levels in Children With AR · NA · not yet recruiting
- NCT07524712 — Effects of Energy Versus Mechanical Surgical Devices on Postoperative Cough · NA · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT03750890 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Tongji Hospital
- Last refreshed: 26 March 2019
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03750890.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing